Amgen stock reports 9.5 percent Q2 revenue growth

Published on 10/04/2026 at 18:15 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Amgen stock closed at USD 403.04 on October 2 after a 1.04 percent decline. Q2 EPS reached USD 6.29, beating consensus by USD 0.67.

Editorial-Aufnahme eines Nasdaq-Handelssaals mit großen Bildschirmen und steigenden Biotech-Sektor-Kurscharts — Amgen Inc. (ISIN US0311621009) thematisiert dieses Börsen-Editorial mit Nasdaq-Handelssaal und ansteigenden Biotech-Sektor-Kurscharts auf großen Bildschirmen, Illustration mit AI erstellt.

Amgen (ISIN US0311621009) reported Q2 revenue growth of 9.5 percent to USD 10.05 billion, while EPS reached USD 6.29 against a USD 5.62 consensus estimate. The shares closed at USD 403.04 on Nasdaq on October 2, 2026, down 1.04 percent.

Q2 beat supports the outlook

According to MarketBeat on September 23, 2026, Amgen's Q2 EPS exceeded consensus by USD 0.67, while revenue surpassed the USD 9.43 billion estimate by USD 0.62 billion. The company maintained fiscal 2026 EPS guidance of USD 22.30-23.50.

The operating comparison is material for the valuation: Q2 revenue increased 9.5 percent year over year, and prior-year EPS was USD 6.02. The latest quarter therefore combined higher sales with a USD 0.27 per-share increase over the prior-year figure.

Dazodalibep expands the pipeline

Amgen's September 22, 2026 release said its Phase 3 OASIZ 301 study of dazodalibep met its primary endpoint at Week 48 in adults with moderate-to-severe systemic Sjogren's disease. According to Amgen, improvements in disease activity appeared as early as Week 4 and continued through Week 48.

The company said detailed OASIZ 301 data will be presented at a future medical meeting, while the Phase 3 OASIZ 303 study is expected to complete in Q4 2026. That pipeline update adds a development milestone to a business already supported by the Q2 earnings beat.

Analysts remain cautious

MarketBeat reported on September 23, 2026, that 30 ratings firms held a consensus Hold view, with 15 Hold ratings, 11 Buy ratings, 3 Sell ratings and 1 Strong Buy rating. The average 12-month price target was USD 381.32, below the October 2 close of USD 403.04.

Amgen stock stays below its yearly high

Amgen stock closed at USD 403.04 on Nasdaq on October 2, 2026. The session range was USD 401.96-410.16, the 52-week range was USD 288.00-447.03, and market capitalization stood at USD 217.9 billion.